Shimura H, Okajima F, Ikuyama S, Shimura Y, Kimura S, Saji M, Kohn L D
Section on Cell Regulation, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892.
Mol Endocrinol. 1994 Aug;8(8):1049-69. doi: 10.1210/mend.8.8.7997232.
The chimeric chloramphenicol acetyltransferase (CAT) construct, pTRCAT5'-199, containing the TSH receptor (TSHR) minimal promoter, -199 to -39 base pairs (bp), exhibits the thyroid specificity and TSH/cAMP autoregulation evident in TSHR gene expression. The present report shows that a cis-acting element between -189 and -175 bp, which binds thyroid transcription factor-1 (TTF-1), is involved in both activities. The 22 bp between -199 and -178 contains a positive element important for expression of the TSHR minimal promoter in rat FRTL-5 thyroid cells. DNAase I footprinting shows that extracts from functioning FRTL-5, but not non-functioning FRT thyroid or Buffalo rat liver (BRL) cells, protect a region between -189 and -175 bp. The protection is duplicated by TTF-1, and the protected element has only a two-base mismatch from the consensus TTF-1 element identified in the thyroglobulin (TG) and thyroid peroxidase minimal promoters. Gel mobility shift analyses reveal that FRTL-5 thyroid cell nuclear extracts form a specific protein/DNA complex with this region, which is prevented by the TTF-1 binding element from the TG promoter; FRT and BRL cell nuclear extracts do not have TTF-1 and do not form this complex. A role for the TSHR/TTF-1 binding element in thyroid-specific expression of the TSHR gene is evidenced as follows. Overexpression of TTF-1 in FRT or BRL cells, which have no TTF-1, increased the activity of pTRCAT5'-199, but not pTRCAT5'-177, which has no TTF-1 binding element. A nonsense mutation of the TTF-1 binding element eliminated TTF-1-induced activation of TSHR promoter activity in FRT or BRL cells and reduced TSHR promoter activity in FRTL-5 thyroid cells. In contrast, mutation of this element to the TTF-1 consensus sequence of the TG or thyroid peroxidase promoter had no significant influence on TSHR promoter activity. The activity of the TSHR/TTF-1 binding element requires a functioning cAMP response element (CRE). Thus, TTF-1 activity is lost when the CRE site is mutated to a nonfunctional, nonpalindromic sequence; it is, in contrast, maximized when CRE activity is maximized by its mutation to a consensus AP1 element. TTF-1 phosphorylation is important for binding and activity. Thus, binding of TTF-1 to the TSHR/TTF-1 element is phosphatase-sensitive and is increased by treating nuclear extracts with the catalytic subunit of protein kinase A. Overexpression of the catalytic subunit of PKA enhances TTF-1-increased activity of the TSHR minimal promoter.(ABSTRACT TRUNCATED AT 400 WORDS)
嵌合氯霉素乙酰转移酶(CAT)构建体pTRCAT5'-199含有促甲状腺激素受体(TSHR)最小启动子,即-199至-39碱基对(bp),具有TSHR基因表达中明显的甲状腺特异性和TSH/cAMP自调节作用。本报告表明,位于-189至-175 bp之间的一个顺式作用元件与甲状腺转录因子-1(TTF-1)结合,参与了这两种活性。-199至-178之间的22 bp包含一个对大鼠FRTL-5甲状腺细胞中TSHR最小启动子表达至关重要的正性元件。DNA酶I足迹分析表明,功能性FRTL-5细胞的提取物可保护-189至-175 bp之间的区域,而非功能性FRT甲状腺细胞或布法罗大鼠肝(BRL)细胞的提取物则不能。TTF-1可重复这种保护作用,且受保护元件与甲状腺球蛋白(TG)和甲状腺过氧化物酶最小启动子中鉴定的TTF-1共有元件仅有两个碱基错配。凝胶迁移率变动分析显示,FRTL-5甲状腺细胞核提取物与该区域形成特异性蛋白质/DNA复合物,而TG启动子的TTF-1结合元件可阻止这种复合物形成;FRT和BRL细胞核提取物不含TTF-1,也不形成这种复合物。TSHR/TTF-1结合元件在TSHR基因甲状腺特异性表达中的作用如下所述。在没有TTF-1的FRT或BRL细胞中过表达TTF-1,可增加pTRCAT5'-199的活性,但对没有TTF-1结合元件的pTRCAT5'-177没有影响。TTF-1结合元件的无义突变消除了FRT或BRL细胞中TTF-1诱导的TSHR启动子活性激活,并降低了FRTL-5甲状腺细胞中TSHR启动子活性。相反,将该元件突变为TG或甲状腺过氧化物酶启动子的TTF-1共有序列对TSHR启动子活性没有显著影响。TSHR/TTF-1结合元件的活性需要一个功能性的cAMP反应元件(CRE)。因此,当CRE位点突变为无功能的非回文序列时,TTF-1活性丧失;相反,当CRE活性通过突变为共有AP1元件而最大化时,TTF-1活性也最大化。TTF-1磷酸化对其结合和活性很重要。因此,TTF-1与TSHR/TTF-1元件的结合对磷酸酶敏感,且用蛋白激酶A催化亚基处理核提取物可增强这种结合。PKA催化亚基的过表达增强了TTF-1增加的TSHR最小启动子活性。(摘要截断于400字)